Pharmaceuticals

Pharmaceutical exports were 158.7 million USD in 2024, below their 178.6 million USD peak in 2021 [BACI 2024]. The domestic industry's scale does not by itself establish export competitiveness. Dependence on imported inputs, product-specific certification and the regulator's capacity affect access to demanding markets. LDC graduation also changes the legal setting for pharmaceutical intellectual property. This chapter distinguishes the trade record, regulatory capability and transition arrangements.

Trade, inputs and domestic demand

The trade record is the measured core. HS30 exports ran 133.1 million USD in 2017, 148.8 million in 2020, peaked at 178.6 million in 2021, and fell to 167.7 million in 2022, 159.3 million in 2023 and 158.7 million in 2024; dosed medicaments in HS3004 carry 153.0 million of the 2024 total [BACI 2024]. The EPB pharma product series is registered in the cited data with zero rows [EPB 2023], so the headline export figures the industry associations publish could not be confirmed here and the EPB annual reports remain the resolving source. The slip from the peak is the finding: the certification constraint, not the covid disruption, is the most recent fact in the series.

Imports tell the dependency story from two directions. Total HS30 imports were 346.2 million USD in 2024, against 1,605.8 million in 2021 when the covid vaccine purchases ran and 1,096.3 million in 2022 [BACI 2024]. The vaccine line, HS3002, alone was 1,456.2 million USD in 2021 and is still 215.1 million in 2024 [BACI 2024]. The pandemic episode proved both facts about the industry at once: domestic formulation supply held through the shock, and no local vaccine manufacturing existed when the bill arrived.

The input dependence sits one HS chapter down, and the dependency reading of the mirror measures it. Of the 204 pharmaceutical-sector import lines in the 2022 classification, 21 are flagged critical dependencies, led by penicillin and its derivatives, HS294110, at 18.7 million USD with China supplying 66.9 percent, streptomycins, HS294130, at 9.7 million USD with China at 99.95 percent, and the vitamin B1, B6 and C lines in HS2936 in the same China-led pattern [GeoDep 2022]. Insulin medicaments, HS300431, at 17.0 million USD, run 54.8 percent to the United States [GeoDep 2022]. The taka that clears this import bill moved from 85.8 per USD at end 2021 to 122.75 in May 2026 [BIS 2026], a 43 percent rise in the taka price of the dollar that squeezed formulation margins before any API policy answered.

The health wallet is the demand base the industry sells into. The latest Bangladesh National Health Accounts puts total health expenditure at 777,347 million BDT, 77,735 crore, for 2020, with the accounts' own out-of-pocket share of 68.53 percent [MOHFW BNHA 2020], and the WHO series carries the share to 79.31 percent in 2023 [WHO GHO 2023, OOP as share of CHE], or 42.40 USD per person per year [WHO GHO 2023, OOP per capita]. Medicines are the largest component of household health spending on any construction of the accounts, the exact split could not be confirmed here, the BNHA function tables the resolving source. A cash market of that shape, paid retail, uninsured, price sensitive, is what the 202,528 retail drug licences documented below service.

Licensed production and retail distribution

The licensed base is now countable from the regulator's own reports. The Directorate General of Drug Administration counted 893 licensed production units across the allopathic, unani, ayurvedic, homoeopathic and herbal systems in FY2021-22, of which 708 were functional, up from 889 and 692 in FY2020-21; the allopathic segment, the export relevant one, ran 295 units with 220 functional in FY2021-22 against 285 and 206 the year before [DGDA 2022] [DGDA 2021]. The names and market shares of the large groups that dominate the allopathic segment could not be confirmed from the cited sources, the DGDA registration records and the market studies the industry commissions being the resolving sources. The tiering runs quality first: a small export-grade segment holding the certifications foreign buyers demand, a large domestic segment meeting the national floor, and an informal periphery the regulator's enforcement reach counts only at its edges.

Retail is the gate where the out-of-pocket share becomes a purchase. The district tables record 202,528 retail drug licences nationally in FY2021-22, 27,081 of them in Dhaka district alone, with 35,530 retail licences renewed during the year [DGDA 2022]. The regulator inspected 54,839 medicine shops in FY2021-22, recovering from a pandemic low of 36,441 in FY2020-21 [DGDA 2022], which means the median licensed pharmacy was not inspected that year. Price control runs through the same office: DGDA fixes the maximum retail price of domestically produced listed allopathic drugs and sets or resets the maximum retail prices of imported drugs, through a drug pricing committee and a technical subcommittee [DGDA 2022]; the count of products under control is not stated in the reports held and could not be confirmed.

The policy implication the structure carries is that quality upgrading is a public finance question as much as a firm question. The buyer of last resort for certified quality is the state's own procurement chain, and the drug procurement dysfunction chapter 31 documents taxes exactly the certification climb this chapter measures; an industry paid by pooled public demand at enforced quality standards has an anchor the retail cash market cannot provide.

The regulator's laboratory and staffing

DGDA is the industry's export ticket, and its own annual reports now supply the capacity numbers the trade record lacks. The sanctioned structure is 720 posts, of which 389 are filled and 331 vacant in FY2021-22; in the first class cadre, the drug inspectors and directors, 103 of 266 sanctioned posts are filled [DGDA 2022]. The structure has grown from 680 posts in FY2019-20 [DGDA 2020], but the vacancy rate is the operating fact: the authority that must run site inspections, bioequivalence oversight and export certification for the decade's climb is staffed at 54 percent of its sanctioned strength.

The laboratory layer is the strongest fact on the certification clock. The National Control Laboratory's drug wing holds ISO/IEC 17025:2017 accreditation from ANAB since 2018 and the microbiology laboratory from the Bangladesh Accreditation Board since 2017, and in March 2022 the laboratory achieved WHO prequalification for medicine testing, with a vaccine testing wing built alongside [DGDA 2022]. The guideline layer followed: approved instruments now include a bioequivalence study and clinical trial guideline, a biosimilar product registration guideline, good manufacturing practice and pharmacovigilance guidelines, and an antimicrobial consumption surveillance guideline [DGDA 2022]. The pharmacovigilance machinery ran through the covid campaign, with adverse event reporting for the vaccine programme maintained to September 2022 [DGDA 2022].

What the laboratory cannot certify, the export record shows. DGDA issued 2,075 export licences and 1,164 free sale certificates in FY2021-22 [DGDA 2022], an export habit of many small shipments. The regulator's own narrative claims the country now produces high technology products including vaccines, insulin and anti cancer drugs [DGDA 2022]; the 215.1 million USD of vaccine imports in 2024 [BACI 2024] say the vaccine line does not yet substitute at scale. The count that would settle the certification question, the number of WHO prequalified local production sites and products, could not be confirmed from the cited sources, the WHO prequalification lists being the resolving source.

Graduation and pharmaceutical intellectual property

The legal base is the industry's founding condition, and the smooth transition strategy states it plainly. Under the WTO TRIPS Council decision of November 2015, document IP/C/73, least developed countries are not required to protect pharmaceutical product patents until the 1 January 2033 term the decision targets or until they cease to be least developed countries, whichever comes first, and the General Council waiver of 30 November 2015, document WT/L/971, lifts the mailbox and exclusive marketing rights obligations to the same January 2033 date [WTO 2015] [ERD STS 2025]. Bangladesh graduates in November 2026 [UN CDP 2021], so on the reading the government itself carries the waiver lapses at graduation rather than at the 2033 term the decision targets [ERD STS 2025].

The LDC Group's December 2022 proposal at the WTO, that graduating members keep both TRIPS waivers to their full terms, had no decision when the strategy was written, and the strategy lists following it up as a task [ERD STS 2025].

The domestic law, however, has converted the cliff into a managed margin. The Bangladesh Patent Act 2023 keeps pharmaceutical and agrochemical products outside patent protection for as long as the exemption period runs, denies patent protection to drugs invented before graduation on novelty grounds, blocks evergreening patents on minor improvements, permits parallel importation of patented products, and provides compulsory licensing under its Section 36 where a patent holder refuses a licence in a national emergency [ERD STS 2025]. The strategy's assessment is that because Bangladesh produces few patented molecules, the introduction of patent protection is unlikely to cause major disruption, with the residual exposure confined to newly patented drugs, which cannot be copied locally without licence and royalty [ERD STS 2025].

The exposed band is bounded: an estimated 10 to 20 percent of local products are patented drugs, on the UNCTAD reading the strategy cites [ERD STS 2025]. The waiver's export side survives for the countries it was built for: firms may manufacture regardless of patent status and export to other least developed countries and to non-WTO members where the product is not patented, and any WTO member may import from Bangladesh under parallel importation [ERD STS 2025].

Graduation's measurable trade cost arrives through incentives, not tariffs, because destination tariffs on pharmaceuticals are negligible on the strategy's reading [ERD STS 2025]. WTO rules require the export subsidies now provided to medicine and API exporters to be discontinued after graduation, and the study the strategy records puts the cost at a 5.8 to 6.9 percent decline in pharmaceutical exports, roughly 10 to 12 million USD a year [ERD STS 2025]. The domestic side of the dual structure keeps its protection either way: the 13.59 percent MFN simple average tariff [WB WITS 2023] prices the home market, and the bonded warehouse regime chapter 18 carries prices the export side. The decade question for the incentive layer is whether it converts from LDC compensation, which graduation ends, to capability support embodied in the API park and the testing laboratories.

Decisions on certification, inputs and transition rules

Four forces carry FY26 to the FY36 horizon the chapter 15 scenarios assume. First, the legal position is now a known cost rather than an open risk: the existing product basket is protected by the Patent Act 2023 design, and the growth exposure is confined to new molecules and the loss of export incentives [ERD STS 2025]. Second, the certification climb: the WHO prequalified national control laboratory of March 2022 is the credible base [DGDA 2022], and the dials that matter are the prequalified site and product counts, which no cited series measures. Third, the API localization: the park at Gazaria in Munshiganj had 88 plots allotted with several firms building plants as of the FY2021-22 report [DGDA 2022]; its operation since could not be confirmed from the cited sources, and until it produces at scale the formulation surplus rests on imported inputs priced at a dollar that rose 43 percent in taka terms between end 2021 and May 2026 [BIS 2026].

Fourth, the health wallet: the 79.31 percent out-of-pocket share [WHO GHO 2023, OOP as share of CHE] is the demand base, and the prepayment reforms chapter 31 frames would shift the market from retail cash toward pooled procurement, changing margins and raising the quality floor at the same time.

No cited projection available to this chapter targets the pharmaceutical market or export line in 2036, so the chapter treats any such figure as a scenario assumption rather than an established forecast, and the named authors whose work would resolve it are the industry's market studies and the WHO pharmaceutical system reviews. The research base is the thinnest layer: no domestic pharmaceutical R and D spending series is stored, the industry's patent filings could not be confirmed here with the patents office as resolving source, and the university industry link chapter 33 develops supplies pharmacists and chemists but no measured formulation research output.

The decision points with named owners are the WTO transition settlement carried by the Ministry of Commerce, the API park completion carried by the Health Ministry's project implementation, the DGDA staffing and certification investment carried by the Ministry of Health and Family Welfare, and the health procurement reform chapter 31 assigns to the Health Services Division.

Risks and opportunities

Risks. First, the certification plateau: three consecutive annual declines from the 178.6 million USD peak of 2021 [BACI 2024] are the pattern of a sector whose export constraint is approval throughput, and the indicators to monitor are the annual export line and the DGDA export licence count, which at 2,075 licences in FY2021-22 [DGDA 2022] marks the small shipment habit the plateau would extend. Second, the input trap: a further taka shock against 21 China-led critical API lines [GeoDep 2022] squeezes margins while retail prices sit under regulator set maximums, and the indicators to monitor are the exchange rate [BIS 2026] and the API park's operating status.

Third, the new molecule channel: after graduation, newly patented drugs enter at licence and royalty cost, and the strategy's own assessment warns healthcare costs could rise on exactly those therapy classes [ERD STS 2025]; the indicators to monitor are the WTO TRIPS Council record and the HS30 import line [BACI 2024].

Upside. First, the legal clarity is banked: because the Patent Act 2023 embedded the flexibilities before graduation, the worst case that haunted the sector's graduation literature is priced, and the strategy says so [ERD STS 2025]. Second, the certification asset compounds: a WHO prequalified control laboratory, an accredited guideline set and an issuing machine for export certificates are the fixed costs of the export ladder, already paid [DGDA 2022], and the vaccine import bill of 215.1 million USD in 2024 [BACI 2024] is the standing demand that local fill finish would capture first. Third, the domestic anchor: an industry supplying nearly 98 percent of home on a 79.31 percent out-of-pocket cash market [ERD STS 2025] [WHO GHO 2023, OOP as share of CHE] has scale no new entrant in the region matches, and pooled procurement under chapter 31's reforms would convert that scale into the quality-anchored demand the certification climb needs.

Testing the policy case

DGDA and the commerce ministry should track product-specific approvals, inspection outcomes and sustained export orders. More laboratory capacity without faster, credible certification would reveal an implementation gap. Export expansion without improved quality assurance would not justify relaxing regulatory scrutiny.

What to watch

The thresholds below are author-proposed monitoring markers, not official targets or estimated policy effects. Interpret them alongside the source dates and definitions.

1. Pharmaceutical exports. Latest cited value 158.7 million USD in 2024, three years below the 178.6 million USD peak of 2021 [BACI 2024]. Threshold: sustained growth above 20 percent a year marks the certification climb regime; a fourth consecutive annual decline would be consistent with the plateau.
2. Medicine and vaccine imports. Latest cited value 346.2 million USD in 2024, of which the vaccine line is 215.1 million [BACI 2024]. Threshold: a rising trend against flat exports marks deepening dependency; a fall below 200 million USD marks the substitution regime.
3. API park operating status. Current status: 88 plots allotted and several firms constructing plants as of the FY2021-22 report [DGDA 2022]; commercial operation not confirmed since. Threshold: first commercial API production marks the input security regime; no operating output by FY30, the test date the chapter 15 scenarios assume, marks the programme's failure.
4. WHO prequalified production sites and products. Current count: none confirmed, the WHO prequalification lists the resolving source; the prequalified National Control Laboratory of March 2022 is the base beneath it [DGDA 2022]. Threshold: the first prequalified local site opens UN procurement demand; none by FY30, the date the scenarios assume, would be consistent with the certification plateau.
5. Out-of-pocket health share. Latest cited value 79.31 percent in 2023 [WHO GHO 2023, OOP as share of CHE]. Threshold: a fall below 65 percent, the chapter 31 mark, signals pooled procurement arriving; a rise past 80 percent deepens the retail cash market the industry currently sells.

Sources used

[BACI 2024] CEPII bilateral trade at HS6 via the trade/bd_hs6_trade parquet, series: bd_hs6_trade, HS chapter 30 totals and HS3002 and HS3004 lines, values in thousand USD.

[GeoDep 2022] GeoDep critical trade dependency classification on UN Comtrade mirror data, Bangladesh pharma sector lines, series: geodep_crit_pharmaceuticals, via bdpolicy.db and the tradeweave geodep_bd parquet.

[WTO 2015] WTO TRIPS Council decision IP/C/73 of November 2015 on the LDC pharmaceutical transition, term targeted at 1 January 2033 or the date a member ceases to be an LDC, whichever is earlier, and General Council waiver WT/L/971 of 30 November 2015 on mailbox and exclusive marketing rights obligations, , accessed 2026-09-06.

[UN CDP 2021] UN Committee for Development Policy 2021 triennial review and General Assembly resolution A/RES/76/8, scheduled graduation 24 November 2026, , accessed 2026-09-06.

[ERD STS 2025] Bangladesh Smooth Transition Strategy, February 2025, Economic Relations Division: TRIPS waiver reading, Bangladesh Patent Act 2023 Sections 6(2), 27 and 36, UNCTAD 2024 domestic supply and patented share citations, Razzaque et al. 2024b export incentive loss estimate, destination tariff reading, API park and export subsidy record, via ocr_text/policies/ldc-graduation-smooth-transition-strategy__2025.txt.

[DGDA 2020] Directorate General of Drug Administration annual report FY2019-20, sanctioned post structure, via ocr_text/dgda.

[DGDA 2021] Directorate General of Drug Administration annual report FY2020-21, production unit statistics, via ocr_text/dgda.

[DGDA 2022] Directorate General of Drug Administration annual report FY2021-22: production units, district retail licences, renewals, inspections, staffing, National Control Laboratory accreditations and WHO prequalification, guidelines, export certificates, API park plots, price control functions, via ocr_text/dgda.

[MOHFW BNHA 2020] Bangladesh National Health Accounts 2020 via bdpolicy.db, series: bnha_the_current_bdt_mil, bnha_oop_share_pct, total health expenditure 777,347 million BDT and official out-of-pocket share.

[WHO GHO 2023] World Health Organization Global Health Observatory via the health/who_gho_bd parquet, series: OOP as share of CHE, OOP per capita.

[EPB 2023] Export Promotion Bureau pharma product series via bdpolicy.db, series: trade_pharma_exports, registered with zero rows.

[BIS 2026] Bank for International Settlements USD/BDT series via bdpolicy.db, series: bis_usd_bdt_monthly_eop, annual and monthly end of period.

[WB WITS 2023] World Bank World Integrated Trade Solution applied tariff statistics via bdpolicy.db, series: bd_tariff_mfn_simple_avg.